Biogen (NASDAQ: BIIB) director receives 2,005 restricted stock unit award

Rhea-AI Filing Summary

Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.

Biogen director Maria C. Freire received an equity award of 2,005 shares of common stock in the form of restricted stock units. The grant carried no purchase price and represents compensation rather than an open-market trade. Following this award, she directly owns 8,820 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 anniversary of the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Freire Maria C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,005	$0.00	--

Holdings After Transaction: Common Stock — 8,820 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity award size: 2,005 shares Post-grant holdings: 8,820 shares Grant price per share: $0.0000 per share +1 more

4 metrics

Equity award size 2,005 shares Restricted stock unit grant to director on June 9, 2026

Post-grant holdings 8,820 shares Total Biogen common shares directly owned after transaction

Grant price per share $0.0000 per share Restricted stock units granted at no purchase price

Vesting trigger date June 9, 2026 Vest on earlier of next annual meeting or grant anniversary

Key Terms

restricted stock units, Common Stock, grant, award, or other acquisition

3 terms

restricted stock units financial

"The restricted stock units vest on the earlier of (i) the next annual meeting..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Freire Maria C

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		2,005(1)	A	$0	8,820	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

	/s/ Wendell Taylor, attorney-in-fact for Dr. Freire	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Biogen (BIIB) director Maria C. Freire report?

Maria C. Freire reported receiving an equity award of 2,005 Biogen common shares. These were granted as restricted stock units at no purchase price, reflecting director compensation rather than an open-market stock purchase or sale.

How many Biogen (BIIB) shares does Maria C. Freire hold after this Form 4?

After the reported grant, Maria C. Freire directly owns 8,820 Biogen common shares. This total includes the 2,005 shares granted as restricted stock units, as disclosed in the Form 4 filing.

What is the vesting schedule for Maria C. Freire’s new Biogen (BIIB) restricted stock units?

The restricted stock units vest on the earlier of Biogen’s next annual meeting or June 9, 2026. This means the award becomes fully vested at whichever of these two dates occurs first, subject to the stated conditions.

Was Maria C. Freire’s Biogen (BIIB) transaction an open-market stock purchase?

No, the transaction was a grant of 2,005 restricted stock units with a zero purchase price. It is categorized as a “grant, award, or other acquisition,” indicating equity compensation rather than a market trade.

What type of security did Maria C. Freire receive from Biogen (BIIB)?

She received restricted stock units linked to Biogen common stock. The Form 4 describes the security as common stock, with footnotes clarifying that the award takes the form of restricted stock units that vest based on the stated timeline.